Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Tuesday with $20 million in a tranched series A round from Versant

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE